Michel Delforge

Active 1995–2025

106
Papers
19,655
Citations
60
h-index
98
i10-index

Citations

Citations per year for Michel Delforge1988: 2 citations1989: 1 citations1990: 1 citations1997: 4 citations1998: 1 citations1999: 1 citations2000: 2 citations2001: 1 citations2002: 1 citations2003: 2 citations2004: 2 citations2005: 1 citations2006: 2 citations2008: 3 citations2009: 13 citations2010: 18 citations2011: 52 citations2012: 71 citations2013: 91 citations2014: 98 citations2015: 99 citations2016: 137 citations2017: 129 citations2018: 109 citations2019: 490 citations2020: 620 citations2021: 790 citations2022: 822 citations2023: 795 citations2024: 1,466 citations2025: 723 citations2026: 11 citations1991–1996: no citations, so these years are not shown2007: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,049 citing papers, 23.1% of this breakdownGermany: 617 citing papers, 7% of this breakdownChina: 583 citing papers, 6.6% of this breakdownItaly: 500 citing papers, 5.6% of this breakdownFrance: 484 citing papers, 5.5% of this breakdownUnited Kingdom: 462 citing papers, 5.2% of this breakdownSpain: 445 citing papers, 5% of this breakdownNetherlands: 332 citing papers, 3.8% of this breakdownCanada: 298 citing papers, 3.4% of this breakdownGreece: 267 citing papers, 3% of this breakdownBelgium: 259 citing papers, 2.9% of this breakdownAustralia: 208 citing papers, 2.4% of this breakdown
0%23.1%Other 26.5%

Fields

  • Medicine78.2%
  • Biochemistry, Genetics and Molecular Biology10%
  • Immunology and Microbiology10%
  • Computer Science0.3%
  • Economics, Econometrics and Finance0.2%
  • Neuroscience0.2%
  • Other1.1%

Topics

  • Multiple Myeloma Research and Treatments15.9%
  • CAR-T cell therapy research9.8%
  • Protein Degradation and Inhibitors7.4%
  • Peptidase Inhibition and Analysis4.1%
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms2.9%
  • Cancer Treatment and Pharmacology2.6%
  • Other57.3%

Coauthors

All papers

Open in search
  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 2,424

  2. Teclistamab in Relapsed or Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani - New England Journal of Medicine 2022 cited by 1,114

  3. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 705

  4. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau - New England Journal of Medicine 2023 cited by 515

  5. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 820

  6. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Soraya Wuillème, Sonja Zweegman, Brigitte Kolb, Cyrille Touzeau, Murielle Roussel, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Jean Paul Fermand, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Sen Hong Zhuang, Christopher Chiu, Lixia Pei, Carla de Boer, Elena Smith, William Deraedt, Tobias Kampfenkel, Jordan M. Schecter, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet 2019 cited by 953

  7. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 178

  8. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 cited by 240

  9. Neutrophil extracellular trap cell death requires both autophagy and superoxide generation

    Authors: , , , , , , , , , - Cell Research 2010 cited by 806

  10. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn and 30 more - The Lancet 2019 cited by 636

  11. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raymond L. Comenzo, Monika Engelhardt, Thomas Illmer, Philip Vlummens, Chantal Doyen, Thierry Façon, Lionel Karlin, Aurore Perrot, Klaus Podar, Michael Kauffman, Sharon Shacham, Lingling Li, Shijie Tang, Carla Picklesimer, Jean‐Richard Saint‐Martin, Marsha Crochiere, Hua Chang, Samir Parekh, Yosef Landesman, Jatin J. Shah, Paul G. Richardson, Sundar Jagannath - New England Journal of Medicine 2019 cited by 673

  12. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cyrille Touzeau, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Fritz Offner, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Maria Krevvata, Ke Zhang, Carla de Boer, Sanjay Vara, Tobias Kampfenkel, Véronique Vanquickelberghe, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet Oncology 2021 cited by 175

  13. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 65

  14. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2013 cited by 799

  15. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 cited by 77

  16. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annette Ervin‐Haynes, Hervé Avet‐Loiseau, Cyrille Hulin, Thierry Façon - New England Journal of Medicine 2014 cited by 786

  17. Multiple myeloma: patient outcomes in real‐world practice

    Authors: , , , , , , , , , , , - British Journal of Haematology 2016 cited by 321

  18. Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis

    Authors: , , , , , , , - Circulation Cardiovascular Imaging 2017 cited by 298

  19. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ashraf Badros, Philippe Moreau, K Kim, P R Otero, J H Lee, Chaim Shustik, Daniel D. Waller, Wee Joo Chng, Shuji Ozaki, J-J Lee, Javier de la Rubia, Hyeon‐Seok Eom, Laura Rosiñol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, B G M Durie - Leukemia 2017 cited by 354

  20. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Fritz Offner, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Winnie Hua, Jianping Wang, Alba Tuozzo, Carla de Boer, Melissa Rowe, Véronique Vanquickelberghe, Robin Carson, Jessica Vermeulen, Jill Corre, Pieter Sonneveld - The Lancet Oncology 2024 cited by 112

  21. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Haematologica 2018 cited by 112

  22. CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 40

  23. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Paula Rodríguez‐Otero - Blood 2024 cited by 63

  24. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 66